Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1999
Business Overview: The Company operates in three segments: Pharmaceutical Distribution, Pharmaceutical Services, and Medical-Surgical Products. Financial statements have been restated to reflect the pooling of interests mergers with Pacific Surgical, Inc. (May 1999) and Automatic Liquid Packaging, Inc. (September 1999).
Key Financial Metrics
| Metric | Q1 FY2000 (Sep 30, 1999) | Q1 FY1999 (Sep 30, 1998) |
|---|---|---|
| Total Revenue | $6,783.7 million | $5,799.1 million |
| Operating Revenue | $5,829.3 million | $5,017.4 million |
| Gross Margin | $654.8 million (11.23% of Op. Rev.) | $591.4 million (11.79% of Op. Rev.) |
| Operating Earnings | $226.7 million | $183.1 million |
| Net Earnings | $122.0 million | $94.7 million |
| Diluted EPS | $0.43 | $0.33 |
| Cash and Equivalents | $185.4 million | $383.1 million (end of period) |
| Working Capital | $2.5 billion | $2.2 billion (as of June 30, 1999) |
| Long-term Obligations | $1,519.6 million | $1,223.9 million (as of June 30, 1999) |
Cash Flow Summary: Net cash used in operating activities was $178.6 million, primarily driven by a $627.9 million increase in inventories and a $157.8 million increase in trade receivables. Net cash provided by financing activities was $257.5 million, largely due to a $356.0 million net increase in commercial paper.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 17% year-over-year. Operating revenue grew 16%, driven by a 71% growth contribution from the Pharmaceutical Distribution segment and a 20% contribution from Medical-Surgical Products.
- Margin Compression: Gross margin percentage decreased from 11.79% to 11.23%. This was primarily due to a higher mix of lower-margin pharmaceutical distribution business (71% of revenue vs. 68% prior year).
- Merger-Related Costs: Costs increased to $36.8 million from $34.4 million. Significant charges included $31.6 million for the ALP merger and $6.9 million for restructuring related to the R.P. Scherer merger. These were partially offset by a $10.3 million credit related to the Allegiance merger.
- Balance Sheet: Inventories rose significantly to $3,568.0 million (from $2,940.0 million at June 30, 1999) due to precautionary Year 2000 stockpiling and increased business volume. Accounts payable increased by $435.8 million.
Outlook, Risks, and Management Commentary
- Future Merger Costs: Management estimates approximately $89.0 million in additional merger-related costs (net of tax: $56.5 million) will be incurred in future periods, primarily fiscal 2000 and 2001, related to exit costs and integration.
- Year 2000 Readiness: The Company estimates total project costs of $27.0 million. Management believes systems have been remediated to avoid material operational impact, though risks regarding third-party dependencies remain.
- Liquidity: The Company maintains a commercial paper program with $502.0 million outstanding at 5.24% interest. Management believes capital resources are adequate for growth and debt service.
- Legal Contingencies:
- Antitrust Litigation: A class action lawsuit regarding chargeback pricing was dismissed by the Seventh Circuit Court of Appeals; plaintiffs have petitioned the Supreme Court. Exposure is limited to $1 million or 1% of any judgment.
- Latex Glove Litigation: Approximately 469 lawsuits regarding natural rubber latex exposure remain pending. The Company cannot estimate potential loss but expects significant defense costs, with substantial coverage anticipated from insurance.
Investor Verification Checklist
- Verify the sustainability of the 16% revenue growth given the shift toward lower-margin pharmaceutical distribution.
- Monitor the $89.0 million in estimated future merger-related costs and their impact on future earnings.
- Assess the impact of the $627.9 million inventory build-up on future cash flows and potential obsolescence risks post-Year 2000.
- Review the status of the Supreme Court petition regarding the antitrust class action lawsuit.
- Track the resolution of latex glove litigation and the adequacy of insurance coverage for defense costs and potential liabilities.